α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 21, Issue 1, 2012, Pages 59-65

  Geerts, Hugo ^a  

^a In Silico Biosciences   (United States)

Author keywords

7 nicotinic receptor; Alzheimer; Cognitive deficit; Schizophrenia

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; A 844606; ABBF; BENZYLIDENE DERIVATIVE; BUNGAROTOXIN RECEPTOR; GLUTAMIC ACID; ION CHANNEL; JNJ 1930942; LY 1078733; LY 2087101; LY 2087133; MEM 3454; NICOTINIC AGENT; NS 1738; PSAB OFP; S 24795; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; TC 1698; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DESENSITIZATION; DISEASE ASSOCIATION; DRUG POTENCY; DRUG TARGETING; HUMAN; IC 50; NEUROPATHOLOGY; NONHUMAN; REVIEW; SCHIZOPHRENIA; SMOKING;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84555217920     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.633510     Document Type: Review

References (51)

1. Thomsen MS, Hansen HH, Timmerman DB, et al. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010;16:323-43
2. Parikh V, Ji J, Decker MW, et al. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci 2010;30:3518-30
3. Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 2001;86:3043-55 (Pubitemid 33139070)
4. Alkondon M, Pereira EF, Eisenberg HM, et al. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000;20:66-75 (Pubitemid 30220492)
5. De Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996;22:405-9 (Pubitemid 26295343)
6. Sullivan JP, Donnelly-Roberts D, Briggs CA, et al. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996;35:725-34 (Pubitemid 26308549)
7. Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306:407-20 (Pubitemid 36734399)
8. Eaton JB, Peng JH, Schroeder KM, et al. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 2003;64:1283-94 (Pubitemid 37532218)
9. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006;63:907-15 (Pubitemid 44192334)
10. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 2003;23:3176-85
11. Tu B, Gu Z, Shen JX, et al. Characterization of a nicotine-sensitive neuronal population in rat entorhinal cortex. J Neurosci 2009;29:10436-48
12. Parri RH, Dineley TK. Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 2010;7:27-39
13. Gay EA, Klein RC, Yakel JL. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther 2006;316:835-42 (Pubitemid 43131013)
14. Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull 2005;64:519-24 (Pubitemid 40082503)
15. Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-36 (Pubitemid 36617980)
16. Parri HR, Hernandez CM, Dineley KT. Research update: alpha7. nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 2011;82(8):931-42
17. van Duijn CM, Hofman A. Relation between nicotine intake and Alzheimer's disease. BMJ 1991;302:1491-4
18. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-3 (Pubitemid 28279707)
19. Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking. protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 1997;94:450-4 (Pubitemid 27483209)
20. Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, et al. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 2009;15:195-202
21. Chatterjee PK, Al-Abed Y, Sherry B, Metz CN. Cholinergic agonists. regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am J Physiol Cell Physiol 2009;297:C1294-306
22. Gronlien JH, Hakerud M, Ween H, et al. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007;72:715-24 (Pubitemid 47347306)
23. Biton B, Bergis OE, Galli F, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007;32:1-16 (Pubitemid 44967780)
24. Werner P, Kawashima E, Reid J, et al. Organization of the mouse 5-HT3 receptor gene and functional expression of two splice variants. Brain Res Mol Brain Res 1994;26:233-41
25. Briggs CA, Schrimpf MR, Anderson DJ, et al. Alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues. Br J Pharmacol 2008;153:1054-61 (Pubitemid 351328941)
26. Boess FG, De Vry J, Erb C, et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo [2.2.2]oct-3-yl]-7-[2- (methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007;321:716-25 (Pubitemid 46624485)
27. Mullen G, Napier J, Balestra M, et al. (-)-Spiro[1-azabicyclo[2.2.2] octane-3,5¢-oxazolidin-2¢-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 2000;43:4045-50
28. Kem WR, Mahnir VM, Prokai L, et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol 2004;65:56-67 (Pubitemid 38113886)
29. Machu TK, Hamilton ME, Frye TF, et al. Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine(3A) receptor. J Pharmacol Exp Ther 2001;299:1112-19 (Pubitemid 33104983)
30. Dinklo T, Shaban H, Thuring JW, et al. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazoleme thanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 2011;336:560-74
31. Broad LM, Zwart R, Pearson KH, et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 2006;318:1108-17 (Pubitemid 44268317)
32. Mazurov A, Hauser T, Miller CH. Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 2006;13:1567-84 (Pubitemid 43821705)
33. Timmermann DB, Gronlien JH, Kohlhaas KL, et al. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 2007;323:294-307 (Pubitemid 47443280)
34. Hajos M, Hurst RS, Hoffmann WE, et al. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo [2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 2005;312:1213-22 (Pubitemid 40293783)
35. Broad LM, Felthouse C, Zwart R, et al. PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol 2002;452:137-44 (Pubitemid 35291059)
36. Lopez-Hernandez G, Plac zek AN, Thinschmidt JS, et al. Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 2007;53:134-44 (Pubitemid 47125947)
37. Marrero MB, Papke RL, Bhatti SS, et al. The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J Pharmacol Exp Ther 2004;309:16-27 (Pubitemid 38393109)
38. Hajos M, Rogers BN. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr Pharm Des 2010;16:538-54
39. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63:630-8 (Pubitemid 43848294)
40. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-7
41. Shytle RD, Silver AA, Sheehan KH, et al. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety 2002;16:89-92 (Pubitemid 35334663)
42. Tregellas JR, Tanabe J, Rojas DC, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2011;69:7-11
43. Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007;11:491-507 (Pubitemid 47094024)
44. Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005;62:721-8 (Pubitemid 40656086)
45. Freedman R, Leonard S, Gault JM, et al. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 2001;105:20-2
46. Geerts H. Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 2009;23:915-26
47. Buccafusco JJ. Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. J Alzheimers Dis 2008;15:709-20
48. Toyohara J, Sakata M, Wu J, et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009;23:301-9
49. Toyohara J, Ishiwata K, Sakata M, et al. In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys. PLoS One 2010;5:e8961
50. Ettrup A, Mikkelsen JD, Lehel S, et al. 11C-NS14492 as a novel PET radioligand for imaging cerebral {alpha}7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med 2011;52:1449-56
51. Vijayraghavan S, Wang M, Birnbaum SG, et al. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007;10:376-84